醋酸甲地孕酮联合他莫昔芬治疗子宫内膜癌的疗效及其对血清TSGF、PRL、HE4的影响

高天明; 付强; 丛丽莉; 崔晨丽; 柳青

PDF(733 KB)

武警医学 ›› 2020, Vol. 31 ›› Issue (4) : 313-316.

论著

醋酸甲地孕酮联合他莫昔芬治疗子宫内膜癌的疗效及其对血清TSGF、PRL、HE4的影响

高天明¹, 付强¹, 丛丽莉¹, 崔晨丽¹, 柳青²

作者信息 +

Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer

GAO Tianming¹, FU Qiang¹, CONG Lili¹, CUI Chenli¹, LIU Qing²

Author information +

文章历史 +

摘要

目的探讨醋酸甲地孕酮联合他莫昔芬治疗子宫内膜癌的疗效及其对血清TSGF、PRL、HE4的影响。方法选择大连大学附属中山医院2016-03至2018-12收治的105例子宫内膜癌患者,随机分成2组。对照组50例,给予口服醋酸甲地孕酮片治疗;观察组55例,给予口服醋酸甲地孕酮片联合枸橼酸他莫昔芬片,治疗12周后,观察两组近期治疗效果及不良反应发生的情况,并采用酶联免疫吸附试验(ELISA法)分别检测两组患者治疗前后血清中TSGF、PRL、HE4表达水平。结果治疗12周后,对照组有效率为42.00%,临床获益率为68.00%;观察组有效率为65.45%,临床获益率为85.45%;两组治疗的有效率及临床获益率的差异均有统计学意义(P＜0.05);两组患者血清TSGF、PRL、HE4表达水平均较治疗前明显降低,差异有统计学意义(P＜0.01),两组间比较发现,观察组患者血清TSGF、PRL、HE4表达水平明显低于对照组,两组差异均有统计学意义(P＜0.05);观察组不良反应发生率明显低于对照组,差异有统计学意义(P＜0.05)。结论醋酸甲地孕酮与他莫昔芬联合治疗有助于提高子宫内膜癌临床治疗效果,降低患者血清TSGF、PRL、HE4表达水平,其发挥临床疗效可能与血清TSGF、PRL、HE4的表达有关。

Abstract

Objective To investigate the clinical efficacy of medroxyprogesterone acetate combined with tamoxifen in the treatment of endometrial cancer and its effect on serum levels of TSGF, PRL and HE4.Methods 105 patients with endometrial cancer admitted to the hospital from March 2016 to December 2018 were randomly divided into 2 groups. 50 cases in the control group were treated with medroxyprogesterone acetate tablets, 55 cases in the observation group were treated with medroxyprogesterone acetate tablets combined with tamoxifen citrate tablets. After 12 weeks of treatment, the recent treatment effect and adverse reactions of the two groups were observed, and the expression levels of TSGF, PRL and HE4 in the serum of the two groups before and after treatment were detected by enzyme-linked immunosorbent assay (ELISA).Results After 12 weeks of treatment, the effective rate of the control group was 42.00%, the clinical benefit rate was 68.00%; the effective rate of the observation group was 65.45%, the clinical benefit rate was 85.45%; the difference of the effective rate and the clinical benefit rate between the two groups was statistically significant (P The results showed that the expression of TSGF, PRL and HE4 in the serum of the patients in the observation group was significantly lower than that in the control group (P<0.05); the incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05).Conclusions Medroxyprogesterone acetate combined with tamoxifen can improve the clinical therapeutic effect of endometrial cancer and reduce the expression level of serum TSGF, PRL and HE4. Its clinical effect may be related to the expression of serum TSGF, PRL and HE4.

导出引用

高天明, 付强, 丛丽莉, 崔晨丽, 柳青. 醋酸甲地孕酮联合他莫昔芬治疗子宫内膜癌的疗效及其对血清TSGF、PRL、HE4的影响[J]. 武警医学. 2020, 31(4): 313-316

GAO Tianming, FU Qiang, CONG Lili, CUI Chenli, LIU Qing. Effect of megestrol acetate combined with tamoxifen on serum levels of TSGF, PRL and HE4 in patients with endometrial cancer[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(4): 313-316

中图分类号： R969.4

参考文献

[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA: A Cancer J Clin, 2011, 61(2): 69-90.
[2] 杨曦, 马珂, 吴成. 子宫内膜癌的流行病学及高危因素[J]. 实用妇产科杂志, 2015, 31(7): 485-488.
[3] Adamiak-Godlewska A, Tarkowski R, Winkler I, et al. Stress urinary incontinent women, the influence of age and hormonal status on estrogen receptor alpha and beta gene expression and protein immunoexpression in paraurethral tissues[J]. J Physiol Pharmacol, 2018, 69(1):53-59.
[4] 张凯, 郭飞, 王颖梅, 等. 新辅助化疗在中晚期子宫内膜癌治疗中的研究进展[J]. 中国妇产科临床杂志, 2018, 19(1): 87-89.
[5] 张一琼, 于江燕, 朱元方. 子宫内膜癌肿瘤微环境的研究进展[J]. 现代肿瘤医学, 2016, 24(16):2651-2655.
[6] 王志启. 醋酸甲地孕酮和他莫昔芬治疗晚期子宫内膜癌的Ⅱ期试验－GOG的一项研究[J]. 国际妇产科学杂志, 2004, 31(6): 390-391.
[7] 符晶莹. 复方苦参注射液联合醋酸甲地孕酮治疗子宫内膜癌的疗效观察[J]. 现代药物与临床, 2016, 31(6): 855-858.
[8] 周际昌, 谢惠民. 新编抗肿瘤药物临床治疗手册[M]. 北京: 中国协和医科大学出版社, 2004: 237-386.
[9] Trotti A, Bentzen S M. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol, 2004, 22(1): 19-22.
[10] 步华磊, 靳成娟, 王霞, 等. 子宫内膜癌卵巢转移高危因素的Meta分析[J]. 现代妇产科进展, 2017, 26(4): 287-292.
[11] 李海萍. HIF-1α、CXCR4及VEGF在子宫内膜癌组织中的表达及意义[J]. 中国老年学杂志, 2017, 37(15): 3782-3784.
[12] 虞斌, 许培箴, 王秋伟,等. 肿瘤特异性生长因子在子宫内膜癌的应用价值[J]. 中国现代医学杂志, 2005, 15(14): 2199-2201.
[13] 邵志翔, 王晓芳. CEA、TSGF以及CA19-9联合检测在胃癌诊疗中的临床价值[J]. 中国实验诊断学, 2017, 21(2): 228-231.
[14] 宋秀军, 刘建红, 吕进. PRL-3在肿瘤中作用机制的研究进展[J]. 临床肿瘤学杂志, 2017, 22(6):566-569.
[15] 陈欢欢, 王新会, 李盛, 等. TC方案化疗联合手术对子宫内膜癌患者血清TSGF、PRL、HE4及炎性因子水平的影响[J]. 海南医学院学报, 2017, 23(5): 705-708, 712.
[16] 王英, 李佩章, 黄玲莎, 等. HE4和CA153联合表达在预测早期乳腺癌淋巴结转移中的意义[J]. 现代肿瘤医学, 2017, 25(3): 63-65.
[17] Angioli R, Plotti F, Capriglione S, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study[J]. Tumour Biol, 2013, 34(1): 571-576.
[18] 马瑞兰, 李国权, 徐晓颖,等. 血浆催乳素水平与绝经前乳腺癌危险性的关系评估[J]. 蚌埠医学院学报, 2015, 40(1):64-66.